
Advice: My husband has lost his lust for life (and sex) now that he's on a weight-loss drug
Melanie from Tiverton
Dear Melanie from Tiverton, or 'Tivvy' as we West Countryfolk call it,
This is possibly the most on-trend question I've had.
The first thing to say is his body is his, not yours, but I hear where you're coming from. I went to a big fat English lunch earlier in the month. There were lashings of Léoube, a smorgasbord of River Cafe-level scran, and exquisite wisps floating about in broderie anglaise maxi dresses.
I'm not going to mention the women again as they were the same. No carbs have passed their lips for decades and they weigh less than they did on their wedding days. No, it was the men that jumped out (not literally, from the bushes, but you know what I mean). Around half of them looked different…and somewhat diminished.
In this day and age, we know of course that when men suddenly become thin and listless and silent it's not because they're 'battling' some horrid disease. It's because they've become hooked on weight-loss jabs.
At the lunch, when asked why they were half the men they used to be, the slimmed-down boasted proudly they were on Mounjaro or Ozempic or whatever. I have to say it. Most of them were shadows of their former strapping selves. Instead of the raucous carousing they were known and loved for in their past lives, they sat uneasily at the feast, nursing their sparkling waters and pushing their micro-portions of grilled sea bass with salsa verde around their plates as I went up for seconds and thirds.
As the host joked afterwards, 'next year I'll just lay on some crisps and save myself a fortune!' as many of the blokes were so birdlike in their appetites. And this is the point isn't it. Mounjaro (and the other jabs) are designed to decrease appetite. Of all sorts. Appetite and lust for life. It creates feelings of satiety and fullness even when you've barely touched a morsel.
It also seems to lower the mood. I know a few men on Mounjaro and, like your husband, they seem tired, both of London and of life. Your old man has been turned off the pleasures of the flesh apparently by a drug that is making its manufacturers bigger and bigger as its millions of users become smaller and smaller.
According to anecdotal reports, some reported side effects do include lower libido, erectile changes and flat mood or 'emotional blunting' as the weight drops off – but so does general mojo. And as we all realise as we get older, people are appealing not so much for their outward appearance, but their inner energy.
Big Pharma, its prescribers, makers and users will cite the manifold benefits of losing a lot of timber: improved confidence, self-esteem, cardiovascular health (and that can improve sexual stamina too) and higher testosterone, ie it could indeed prove to be a miracle wonder drug and who are you and I to knock it? Well, in your husband's case, the weight-loss drug has served as a fun- as well as fat-suck. And for others too.
Like you, I've also noticed something… grey about men on the pen. But if you beg men to stop it and say, 'But I preferred you like you were before, all…normal and jolly,' I've noticed they brush you off because they quite understandably love their new svelte physiques more than they loved being the life and soul of the party.
After being the chubby one all their lives, or carrying too much middle-aged spread, it's too late for them to stop the weight jabs now. After a lifetime's bad body image, they have achieved their BMI nirvana and that's all that matters, never mind that they no longer care about sex very much, they can't be arsed and what matters now is not the notches on the bedpost but the belt. The pen is mightier, it turns out, than the penis.
'In terms of advice: until he achieves his target weight, I'd suggest your chap take some supplements such as zinc, magnesium, Omega 3, calcium and Vitamin D, and see whether that increases his sexual appetite.
'Oh yes, when my husband gave up booze for a year – he switched to an alcohol-free beer called Kaliber – I was quite relieved when he started drinking again as it chirped him up (it still does). I missed the Rabelaisian man and good-timer I'd married, so you have my sympathies.'
And also tell your chap this. Men don't love skeletal self-denying women who live on a rocket leaf a day even if it makes them as ripped as Demi Moore, and – newsflash! – nor do women. We like a dad bod (think Jon Hamm in Friends and Neighbours…mmmm….). Unlike men – annoying generalisation alert – we don't find the opposite sex attractive only on the basis of looks alone.
I'd tell him you love him as he is and always will, but fancied him more before, then quickly quote Shakespeare's Julius Caesar before he takes his diet too far.
'Let me have men about me that are fat, sleek-headed men and such as sleep a-nights. Yond Cassius has a lean and hungry look' etc. And then tell him he's gorgeous and seduce him.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

1News
4 days ago
- 1News
Ozempic and other weight-loss drugs linked to rare but serious eye conditions
Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world, say researchers Flora Hui and Pete A Williams. Collectively known as GLP-1 agonists, these drugs mimic the hormone GLP-1. This limits both hunger and interest in food, helping users lose weight, and helps control blood sugar levels. But two new studies published today show that people taking these drugs may have a small increased risk of serious eye conditions and vision loss. Here's what you need to know if you're taking or considering these medications. What damage can occur? ADVERTISEMENT Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked. It's also called an 'eye stroke'. The exact cause of NAION remains unclear and there are no current treatments available. People with diabetes are at increased risk of developing NAION. Unlike other eye conditions that develop gradually, NAION causes a sudden, painless loss of vision. Patients typically notice the condition when they wake up and discover they've lost vision in one eye. Vision tends to worsen over a couple of weeks and slowly stabilises. Recovery of vision is variable, but around 70% of people do not experience improvement in their vision. What has previous research shown? A previous study from 2024 found participants prescribed semaglutide for diabetes were four times more likely to develop NAION. For those taking it for weight loss, the risk was almost eight times higher. In June, the European Medicines Agency concluded NAION represented a 'very rare' side effect of semaglutide medications: a one in 10,000 chance. In a first for medicines regulators, the agency now requires product labels to include NAION as a documented risk. ADVERTISEMENT However the recent studies suggest the risks may be lower than we first thought. In addition to NAION, there is also evidence to suggest GLP-1 drugs can worsen diabetic eye disease, also known as diabetic retinopathy. This occurs when high blood sugar levels damage the small blood vessels in the retina, which can lead to vision loss. It may sound counter-intuitive, but rapid blood sugar reductions can also destabilise the fragile blood vessels in the retina and lead to bleeding. What do the new studies say? Two newly published studies investigated people with type 2 diabetes living in the United States over two years. The studies looked at the medical records of 159,000 to 185,000 people. One study found semaglutide or tirzepatide was associated with a more modest risk of developing NAION than previously thought. Of 159,000 people with type 2 diabetes who were taking these drugs, 35 people (0.04%) developed NAION, compared with 19 patients (0.02%) in the comparison group. The researchers also found an increased risk of developing 'other optic nerve disorders'. However, it's unclear what kind of optic nerve disorders this includes, as the medical record codes used didn't specify. ADVERTISEMENT Counter to this, the second study did not find an increased risk of NAION among those taking GLP-1 drugs. However, the researchers found a small increase in the number of people developing diabetic retinopathy in those prescribed GLP-1 drugs. But overall, participants on GLP-1 drugs experienced fewer sight-threatening complications related to their diabetic retinopathy and required less invasive eye treatments compared to the group taking other diabetes medications. Further studies are still needed to understand how GLP-1 drugs can lead to eye complications. A current, five-year clinical trial is studying the long-term effects of semaglutides and diabetic eye disease in 1,500 people, which should tell us more about the ocular risks in the future. What does this mean for people taking GLP-1 drugs? NAION is a serious condition. But we need to strike a balance between these (and other) risks and the benefits of GLP-1 medications in diabetes care, obesity treatment, reducing heart attack risks and extending lives. The key lies in informed decision-making and identifying different levels of risk. ADVERTISEMENT People with multiple NAION risk factors – such as sleep apnoea, high blood pressure and diabetes – should undergo careful consideration with their treating doctor before starting these medications. 'Crowded' optic nerve heads are also a risk factor for NAION. This is an anatomical feature where blood vessels at the optic nerve head are tightly packed together. People with crowded optic nerve heads should also undergo careful consideration before starting GLP-1 medications. Although NAION can strike without warning, regular comprehensive eye examinations with your optometrist or ophthalmologist still serve important purposes. They can detect other drug-related eye problems, including worsening diabetic retinopathy, and can identify patients with crowded optic nerve heads. It's also important to tell them if you are taking GLP-1 medications so they can keep a close watch on your eye health. Emerging research also suggests that improving your heart health might help reduce risks of developing NAION. This includes proper management of high blood pressure, diabetes and cholesterol – all conditions that compromise the small blood vessels feeding the optic nerve. Studies also show patients with heart conditions who better adhere to their medication prescriptions have lower risks of NAION than those who don't. Doctors should discuss NAION risks during prescribing decisions and work with eye care providers to monitor regularly for diabetic eye disease. Patients need clear instructions to seek immediate medical attention for sudden vision loss and the need for regular eye examinations. Aggressive treatment of sleep apnoea and other heart conditions may also help reduce NAION risks. But for now, there remains an ongoing need for more research to understand how GLP-1 medications can affect the eye. ADVERTISEMENT Flora Hui is a research fellow at the Centre for Eye Research Australia and honorary fellow at the Department of Surgery (Ophthalmology), at the University of Melbourne, Australia. Pete A Williams is a Ulla and Ingemar Dahlberg Professor in Vision Science and a research group leader, at Karolinska Institutet in Stockholm, Sweden. This article is republished from The Conversation under a Creative Commons license.


NZ Herald
7 days ago
- NZ Herald
Three diets that stimulate the same hormone as weight-loss drugs – without the side effects
Some GPs are quietly proving that targeted diet and lifestyle programmes can achieve similar results to Mounjaro, Wegovy and Ozempic. The weight-loss jab boom is in full swing. With celebrities showing off dramatic transformations, #ozempicbody trending on TikTok, and many buying GLP-1 drugs like Mounjaro, Wegovy and Ozempic to slim


Scoop
07-08-2025
- Scoop
BestStart Raises $91,000 For Whānau Āwhina Plunket
BestStart early education centres around the country have raised a total of $91,000 to support Whānau Āwhina Plunket, thanks to their 2025 BestStart Butterfly Appeal. The money helps Plunket to deliver free community services for families, including home visits, new parent groups and parenting programmes. 'This is the 10th year that BestStart have supported us with this amazing appeal – and they generated a record-breaking total this year – we are so grateful for their efforts, '' says Fiona Kingsford, Whānau Āwhina Plunket Chief Executive. 'All sorts of fun activities for tamariki go into the BestStart Butterly Appeal fundraiser, from face- painting to teddy bear picnics and more, we truly appreciate it.' Over the past 10 years, BestStart centres around the country have raised an incredible $483,000 to support Whānau Āwhina Plunket's community services, Fiona says. 'BestStart and Plunket are both committed to making a positive difference in the lives of tamariki and their whānau. Our butterfly logo symbolises growth, care and transformation; values shared by both organisations.' BestStart Howick topped the appeal, raising $2,043. Each team member cooked a dish from a different culture, and they held a Friday takeaway night for local families. 'We are so happy to be this year's top fundraiser, as it so aptly matches with our philosophy of 'Bringing communities together from the heart'. This time it was bringing communities together through delicious food,' says Centre Manager, Philomena Lobo. About Whānau Āwhina Plunket: Pēpi, tamariki and whānau are at the heart of Whānau Āwhina Plunket. The charity is Aotearoa New Zealand's largest health and wellbeing support service for tamariki – seeing 290,000 under-fives in 2024. About three-quarters of newborns are enrolled with Whānau Āwhina Plunket each year. Our nurses provide clinical assessments, and along with Kaiāwhina and Community Karitāne, support whānau and families, through home and clinic visits, as well as PlunketLine 0800 933 922, a free 24/7 telephone advice service for parents. Our website is one of the country's most widely read digital child health resources, with 1.8 million visits each year. It is available data-free through the Zero Data portal at and you can choose to view it in English or te reo Māori.